BRAF and cancer: We also found 22 recurrent mutations across 13 cancer types (>1 PDX model) in 10 druggable target genes: PIK3CA, FGFR (FGFR1, FGFR3), AKT1, BRAF, PTEN, BRCA2, ERBB2, KIT, and NF1, which, respectively, matched NCI-MATCH drugs copanlisib, erdafitinib, capivasertib, dabrafenib with trametinib (or ulixertinib), GSK2636771, adavosertib, afatinib, sunitinib malate, and trametinib (Fig. 7b).